

10-23-03

FSUM 10461.21  
PATENT



Express Mail No. EL 998648613 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Robert A. Holton et al.

Art Unit 1626

Serial No. 10/618,063

Filed July 11, 2003

Confirmation No. 4325

For C10 CARBAMOYLOXY SUBSTITUTED TAXANES

October 22, 2003

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

**INFORMATION DISCLOSURE STATEMENT**

\* Applicants submits herewith, in accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record herein. Copies of the references cited have not been provided in accordance with 37 C.F.R. § 1.98(d) because they are of record in prior application Serial No. 09/775,852, filed February 2, 2001, now U.S. Patent No. 6,596,737 B2, relied upon for an earlier filing date under 35 U.S.C. § 120.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b) in that applicants believe that it is being filed prior to the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is required. If an Office action was issued prior to the mailing of this Statement, the Commissioner is hereby authorized to charge any fees associated with this Statement to Account No. 19-1345.

Respectfully submitted,

Bradley S. Schammel, Reg. No. 54,667  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

BSS/vlm  
\*Enclosure

PTO/SB/08A				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/618,063
				Filing Date	July 11, 2003
				Confirmation Number	4325
				First Named Inventor	Robert A. Holton
				Group Art Unit	1626
				Examiner Name	TBA
Sheet	1	of	4	Attorney Docket No.	FSUM 10461.21


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1	5,175,315		Holton, R.A.	12-29-1992
	2	5,227,400		Holton et al.	07-13-1993
	3	5,243,045		Holton et al.	09-07-1993
	4	5,283,253		Holton et al.	02-01-1994
	5	5,350,866		Holton et al.	09-27-1994
	6	5,430,160		Holton, R.A.	07-04-1995
	7	5,556,878		Kelley et al.	09-17-1996
	8	5,567,614		Patel et al.	10-22-1996
	9	5,714,513		Holton et al.	02-03-1998
	10	5,721,268		Holton et al.	02-24-1998
	11	5,780,653		Tao et al.	07-14-1998
	12	5,811,452		Ojima et al.	09-22-1998
	13	5,879,929		Patel, R.N.	03-09-1999
	14	5,906,990		Bouchard et al.	05-25-1999
	15	5,912,264		Wittman et al.	06-15-1999

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  				<b>Complete if Known</b>	
				Application Number	10/618,063
				Filing Date	July 11, 2003
				Confirmation Number	4325
				First Named Inventor	Robert A. Holton
				Group Art Unit	1626
				Examiner Name	TBA
Sheet	2	of	4	Attorney Docket No.	FSUM 10461.21

	16	5,959,125		Bouchard et al.	09-28-1999
	17	6,100,411		Ojima, I.	08-08-2000

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
	18	EP	0 524 093	A1	Rhone-Poulenc Rorer SA	01-20-1993	
	19	EP	0 558 959	A1	Bristol-Myers Squibb Co.	09-08-1993	
	20	EP	0 600 517	B1	Bristol-Myers Squibb Co.	06-08-1994	
	21	EP	0 629 701	B1	Bristol-Myers Squibb Co.	12-21-1994	
	22	WO	93/02065	A1	Rhone-Poulenc Rorer	02-04-1993	
	23	WO	93/23389	A1	Rhone-Poulenc Rorer	11-25-1993	
	24	WO	96/13495	A1	The Research Foundation of State University of New York	05-09-1996	
	25	WO	97/09979	A1	Florida State University	03-20-1997	
	26	WO	97/32578	A1	The Research Foundation of State University of New York	09-12-1997	
	27	WO	97/42181	A1	Florida State University	11-13-1997	
	28	WO	98/02426	A1	Kabushiki Kaisha Yakult Honsha	01-22-1998	
	29	WO	99/09021	A1	Florida State University	02-25-1999	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/618,063
				Filing Date	July 11, 2003
				Confirmation Number	4325
				First Named Inventor	Robert A. Holton
				Group Art Unit	1626
				Examiner Name	TBA
Sheet	3	of	4	Attorney Docket No.	FSUM 10461.21

	30	WO	99/14209	A1	Kabushiki Kaisha Yakult Honsha	03-25-1999	
	31	WO	99/32473	A1	Kabushiki Kaisha Yakult Honsha	07-01-1999	
	32	WO	00/53592	A1	Asahi Kasei Kogyo Kabushiki Kaisha	09-14-2000	
	33	WO	01/57013	A1	Florida State University Research Foundation, Inc.	08-09-2001	

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	34	GUERITTE-VOEGELEIN et al. "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity" Journal of Medicinal Chemistry, Vol. 34, No. 3 (1991) pp. 992-998	
	35	KANT et al. "A Chemoselective Approach to Functionalize the C-10 Position of 10-Deacetylbaccatin III. Synthesis and Biological Properties of Novel C-10 Taxol Analogues" Tetrahedron Letters, Vol. 35, No. 30 (1994) pp. 5543-5546	
	36	KIRIKAE et al. "Structural Significance of the Acyl Group at the C-10 Position and the A Ring of the Taxane Core of Paclitaxel for Inducing Nitric Oxide and Tumor Necrosis Factor Production by Murine Macrophages" FEBS Letters, Vol. 478 (2000) pp. 221-226	
	37	OJIMA et al. "Synthesis and Biological Activity of Novel 3'-trifluoromethyl Taxoids" Bioorganic and Medicinal Chemistry Letters, Vol. 7, No. 2 (1997) pp. 133-138	
	38	OJIMA et al. "Enantiopure Fluorine-containing Taxoids: Potent Anticancer Agents and Versatile Probes for Biomedical Problems" Journal of Fluorine Chemistry, Vol. 97 (1999) pp. 3-10	
	39	OJIMA et al. "Synthesis and Structure-Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity Against Drug-Resistant Cancer Cells" Journal of Medicinal Chemistry, Vol. 39, No. 20 (1996) pp. 3889-3896	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/618,063	
			Filing Date	July 11, 2003	
			Confirmation Number	4325	
			First Named Inventor	Robert A. Holton	
			Group Art Unit	1626	
			Examiner Name	TBA	
Sheet	4	of	4	Attorney Docket No.	FSUM 10461.21



	40	OJIMA et al. "Syntheses and Biological Activity of C-3'-Difluoromethyl-Taxoids" Bioorganic & Medicinal Chemistry, Vol. 8 (2000) pp. 1619-1628	
	41	OJIMA et al. "Synthesis of Novel 3'-Trifluoromethyl Taxoids Through Effective Kinetic Resolution of Racemic 4-CF <sub>3</sub> -β-Lactams With Baccatins" Chirality, Vol. 9 (1997) pp. 487-494	
	42	STRAUBINGER et al. "Pharmacology and Antitumor Effect of Novel Placlitaxel Formulations" Chapter 8, Edited by G. Georg et al., Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583, 207th National Meeting of the American Chemical Society, San Diego, CA (1994) pp. 111-123	
	43	International Search Report from PCT/US01/03633 dated June 11, 2001	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.